Navigation Links
Heptares to Moderate Panel on Global Business Development at Upcoming Boston Biotech East/West CEO Conference
Date:1/8/2014

WELWYN GARDEN CITY, England and BOSTON, January 8, 2014 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery and development company, notes that its President, Dan Grau, will moderate a panel discussion entitled "Global Entrepreneurs: Biotech Building Beyond Borders" (1:30-2:00pm Eastern time on 11 January) at the Boston Biotech East/West CEO Conference, which takes place at the Four Seasons Hotel, San Francisco, CA, USA on 11-12 January.

Mr Grau, Malcolm Weir (CEO), Fiona Marshall (CSO) and Barry Kenny (CBO) will attend the JPMorgan Healthcare conference, also in San Francisco, on 13-16 January.

For a full list of events at which Heptares will be present, please visit http://www.heptares.com

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our proprietary structure-based drug design technology platform, we have built an exciting pipeline of novel drug candidates with the potential to transform the treatment of serious diseases, including Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraine. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com

HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;

StaR is a registered trademark in the EU and Japan.


'/>"/>
SOURCE Heptares Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Heptares Initiates Clinical Study With First Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimers Disease
2. Heptares Achieves First Research Milestone in Research Collaboration with Cubist
3. Heptares Augments Business Development Capabilities in Japan and Other Asian Territories
4. Heptares to Present at Boston Biotech BD and Future Leaders in the Biotech Industry Conferences
5. Heptares to Present at the 6th Annual European Life Sciences CEO Forum (5-6 March)
6. Heptares to Present at 5th CNS Partnering and Deal-Making Conference (13-14 SEPTEMBER)
7. Heptares and UK Medical Research Council Extend GPCR Collaboration
8. Turkish Diagnostic Imaging System Market Will Fluctuate, While Russian Market Will Grow Moderately Through 2022
9. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
10. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
11. Greater Efficacy on Cognition and Function Over Current Treatments Remain Neurologists Top Unmet Need in Mild to Moderate Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
Breaking Medicine News(10 mins):